Henry Schein, Inc. (NASDAQ:HSIC – Free Report) – Barrington Research dropped their Q1 2025 earnings per share (EPS) estimates for shares of Henry Schein in a note issued to investors on Thursday, January 30th. Barrington Research analyst M. Petusky now expects that the company will post earnings per share of $1.06 for the quarter, down from their prior forecast of $1.12. Barrington Research currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Barrington Research also issued estimates for Henry Schein’s Q2 2025 earnings at $1.20 EPS, Q3 2025 earnings at $1.22 EPS, Q4 2025 earnings at $1.37 EPS and FY2025 earnings at $4.85 EPS.
Henry Schein (NASDAQ:HSIC – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.17 by $0.05. The company had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. Henry Schein’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the previous year, the business earned $1.32 EPS.
View Our Latest Research Report on HSIC
Henry Schein Stock Up 0.2 %
NASDAQ HSIC opened at $80.03 on Friday. The business has a fifty day moving average price of $73.31 and a 200 day moving average price of $71.34. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The company has a market cap of $9.98 billion, a P/E ratio of 32.93, a P/E/G ratio of 2.20 and a beta of 0.89. Henry Schein has a one year low of $63.67 and a one year high of $82.63.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Cromwell Holdings LLC increased its stake in shares of Henry Schein by 93.4% during the third quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after acquiring an additional 170 shares during the period. Studio Investment Management LLC increased its position in Henry Schein by 3.8% during the 3rd quarter. Studio Investment Management LLC now owns 4,674 shares of the company’s stock worth $341,000 after purchasing an additional 172 shares in the last quarter. Central Pacific Bank Trust Division raised its position in shares of Henry Schein by 2.0% in the fourth quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company’s stock valued at $706,000 after buying an additional 200 shares during the last quarter. Huntington National Bank boosted its position in Henry Schein by 16.8% during the third quarter. Huntington National Bank now owns 1,515 shares of the company’s stock worth $110,000 after acquiring an additional 218 shares during the last quarter. Finally, Bridge Creek Capital Management LLC grew its stake in Henry Schein by 0.7% in the 4th quarter. Bridge Creek Capital Management LLC now owns 38,763 shares of the company’s stock worth $2,682,000 after acquiring an additional 260 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.
Insider Buying and Selling
In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the transaction, the chief operating officer now owns 87,706 shares in the company, valued at $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.14% of the stock is owned by company insiders.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also
- Five stocks we like better than Henry Schein
- Industrial Products Stocks Investing
- Starbucks’ CEO-Led Turnaround Gains Traction: New Highs Likely
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Chemical Stocks Defying Tariff Worries With Growth Potential
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- How Growth Investors Find High-Growth Stocks and Maximize Returns
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.